Cosmos Health Achieves Pan-European Distribution for Sky Premium Life Across All 27 EU Member States Through Leading E-Commerce Platform Skroutz
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that its Sky Premium Life nutraceutical and wellness brand is now available for shipment across all 27 EU Member States via leading e-commerce platform Skroutz.
96 products are listed, supporting broader European market penetration, brand visibility and, according to the company, revenue growth.
Positive
- Pan‑EU reach for Sky Premium Life across all 27 EU Member States via Skroutz
- 96 Sky Premium Life products now accessible to consumers across Europe
- Leverages Skroutz cross‑border infrastructure for scalable European distribution
- Supports Cosmos Health’s international growth strategy and global brand positioning
- Company links the initiative to driving revenue growth and expanding global presence
Negative
- None.
News Market Reaction – COSM
In the Jun 4 session, COSM gained 9.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.8% during that session. Argus tracked a trough of -3.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Balance sheet update | Positive | +3.3% | Stronger balance sheet, warrant overhang reduction, and growth guidance highlighted. |
| May 26 | Long-term guidance | Positive | +4.0% | 2026–2029 guidance targeting higher revenue, margins, and positive EBITDA. |
| May 21 | Warrant expiration | Positive | -10.2% | Expiration of 4.87M Series B warrants with no dilution and simpler structure. |
| May 14 | EIB advisory deal | Positive | +1.2% | Advisory agreement for potential EIB venture debt funding up to €25M. |
| May 12 | S-1 withdrawal | Neutral | +0.1% | Withdrawal of Form S-1 for a planned public offering that will not proceed. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent crypto-tag news skew positive fundamentally, but price reactions have been mixed, including one sharp selloff on otherwise constructive warrant-expiration news.
Over the past month, Cosmos Health issued several "crypto"-tagged updates, including balance sheet strengthening, EIB financing discussions of up to €25M, and long-term guidance targeting revenue of $200.6M by 2029. It also highlighted warrant expirations that reduced overhang without dilution and withdrew a planned S-1 offering. Despite generally constructive fundamentals and growth plans, price reactions have ranged from modest gains to a -10.2% drop, showing that positive news has not consistently translated into sustained share strength.
Key Terms
e-commerce technical
cross-border technical
nutraceutical medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now available for shipment across all 27 European Union Member States through Skroutz, significantly expanding the brand’s international reach.
A total of 96 Sky Premium Life products are now accessible to consumers across all 27 European Union Member States through Skroutz, with shipments reaching key markets across Western Europe, Northern Europe, and Central and Eastern Europe. The countries covered include Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.
Skroutz is one of the leading e-commerce platforms in Southeast Europe, connecting millions of consumers with a wide network of merchants and brands. Its cross-border capabilities enable efficient distribution and localized access to products across multiple European markets, making it a strategic channel for international expansion.
The Company believes that this expanded distribution footprint further strengthens the global positioning of the Sky Premium Life brand, enabling broader market penetration and increased accessibility to its portfolio of premium nutraceutical and wellness products.
Greg Siokas, CEO of Cosmos Health, stated: "The expansion of Sky Premium Life across all 27 EU Member States through Skroutz represents a key milestone in our international growth strategy. By leveraging Skroutz’s cross-border infrastructure, we are able to efficiently scale distribution and reach consumers across Europe. This initiative further enhances our brand visibility and supports our continued focus on driving revenue growth and expanding our global presence.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
